Evicenter
P&T meetings

Emiltatug ledadotin (Emi-Le)

Adenoid cystic carcinoma with solid histology or high-grade transformation

Also known as XMT-1660
Manufacturer
Servier
Regulatory submission
Not announced
Launch
Not announced
Last updated
125 sources

Product information and disease descriptionProduct descriptionProduct informationDosing and administration

Administration

2 evidence topics · 2 sources

Route and schedule

“Emi-Le will be administered through a vein in your arm or port catheter (intravenously)” (opens the source at this quote in a new tab)

“Single arm Emi-Le alone (monotherapy)” (opens the source at this quote in a new tab)

“Pts with ACC received Emi-Le at doses of 57.4–89 mg/m2 IV per Q3W or Q4W cycle.” (opens the source at this quote in a new tab)

Pretreatment requirements: brain imaging and tumor tissue

“Tumor tissue, either archival or from a fresh tumor biopsy, available for testing or be willing to undergo a minimally invasive tumor biopsy to obtain tumor tissue for local testing, if not medically contraindicated, prior to Cycle 1 Day 1” (opens the source at this quote in a new tab)

Infusion duration, premedication, and preparation

No evidence found.